Polydatin ameliorates chemotherapy-induced cognitive impairment (chemobrain) by inhibiting oxidative stress, inflammatory response, and apoptosis in rats

References

• Ren X, Boriero D, Chaiswing L, et al. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. Biochimica et Biophysica Acta Mol Basis Dis. 2019 Jun 1;1865(6):1088–1097. PubMed PMID: 30759363; PubMed Central PMCID: PMCPMC6502692. eng.
   PubMed Web of Science ®Google Scholar
• Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007 Sep;5(3):273–280. PubMed PMID: 17969831; eng.
   PubMedGoogle Scholar
• Fardell JE, Vardy J, Johnston IN, et al. Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther. 2011;90(3):366–376.
   PubMed Web of Science ®Google Scholar
• Runowicz CD, Leach CR, Henry NL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73.
   PubMed Web of Science ®Google Scholar
• Fraguas-Sanchez AI, Martin-Sabroso C, Fernandez-Carballido A, et al. Current status of nanomedicine in the chemotherapy of breast cancer. Cancer Chemother Pharmacol. 2019 Jul;31(84):689–706. PubMed PMID: 31367789; eng.
   PubMed Web of Science ®Google Scholar
• Konat GW, Kraszpulski M, James I, et al. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008 Sep;23(3):325–333. PubMed PMID: 18690526; eng.
   PubMed Web of Science ®Google Scholar
• Jansen CE, Dodd MJ, Miaskowski CA, et al. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008 Dec;17(12):1189–1195. PubMed PMID: 18506671; eng.
   PubMed Web of Science ®Google Scholar
• Portela MA, Rubiales AS, Centeno C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care. 2011 Jun;5(2):164–168. PubMed PMID: 21532350; eng.
   PubMedGoogle Scholar
• Davis J, Ahlberg FM, Berk M, et al. Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurol. 2013 Oct;24(13):153. PubMed PMID: 24156319; PubMed Central PMCID: PMCPMC4015674. eng.
   PubMed Web of Science ®Google Scholar
• Wang HL, Gao JP, Han YL, et al. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine. 2015 May 15;22(5):553–559. PubMed PMID: 25981921; eng.
   PubMed Web of Science ®Google Scholar
• Xu LQ, Xie YL, Gui SH, et al. Polydatin attenuates d-galactose-induced liver and brain damage through its anti-oxidative, anti-inflammatory and anti-apoptotic effects in mice. Food Funct. 2016 Nov 9;7(11):4545–4555. PubMed PMID: 27714005; eng.
   PubMed Web of Science ®Google Scholar
• Ji H, Zhang X, Du Y, et al. Polydatin modulates inflammation by decreasing NF-kappaB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 2012 Jan 4;87(1):50–59. PubMed PMID: 22001340; eng.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao S, Zhang Y, et al. Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE cells. J Cell Biochem. 2011 Dec;112(12):3695–3703. PubMed PMID: 21815196; eng.
   PubMed Web of Science ®Google Scholar
• Ye J, Piao H, Jiang J, et al. Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-kappaB and Nrf2/HO-1 pathways. Sci Rep. 2017 Sep 19;7(1):11895. 10.1038/s41598-017-12252-3. PubMed PMID: 28928455; PubMed Central PMCID: PMCPMC5605538. eng.
   PubMedGoogle Scholar
• Du QH, Peng C, Zhang H. Polydatin: a review of pharmacology and pharmacokinetics. Pharm Biol. 2013 Nov;51(11):1347–1354. PubMed PMID: 23862567.
   PubMed Web of Science ®Google Scholar
• Ince S, Arslan Acaroz D, Neuwirth O, et al. Protective effect of polydatin, a natural precursor of resveratrol, against cisplatin-induced toxicity in rats. Food Chem Toxicol. 2014;72:147–153.
   PubMed Web of Science ®Google Scholar
• Huang B, Liu J, Meng T, et al. Polydatin prevents lipopolysaccharide (LPS)-induced Parkinson’s disease via regulation of the AKT/GSK3β-Nrf2/NF-κB signaling axis. Front Immunol. 2018;9:2527. PubMed PMID: 30455692; PubMed Central PMCID: PMCPMC6230593. eng.
   PubMed Web of Science ®Google Scholar
• Chen FY, Fang XY, Zhang H. Effect of polydatin on expression of p53 and Notch1 in brain tissue of ischemic cerebrovascular disease. J Biol Regul Homeost Agents. 2018 Jan–Feb;32(1):133–138. PubMed PMID: 29504377; eng.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen T, Lei X, et al. Neuroprotective effects of polydatin against mitochondrial-dependent apoptosis in the rat cerebral cortex following ischemia/reperfusion injury. Mol Med Rep. 2016 Dec;14(6):5481–5488. PubMed PMID: 27840959; PubMed Central PMCID: PMCPMC5355690. eng.
   PubMed Web of Science ®Google Scholar
• Li RP, Wang ZZ, Sun MX, et al. Polydatin protects learning and memory impairments in a rat model of vascular dementia. Phytomedicine. 2012 Jun 15;19(8–9):677–681. PubMed PMID: 22483554; eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li S, Wang W, et al. Beneficial effects of polydatin on learning and memory in rats with chronic ethanol exposure. Int J Clin Exp Pathol. 2015;8(9):11116–11123. PubMed PMID: 26617831; PubMed Central PMCID: PMCPMC4637646. eng.
   PubMed Web of Science ®Google Scholar
• Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984 May;11(1):47–60. PubMed PMID: 6471907; eng. .
   PubMed Web of Science ®Google Scholar
• Fardell JE, Vardy J, Shah JD, et al. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl). 2012 Mar;220(1):183–193. PubMed PMID: 21894483; eng.
   PubMed Web of Science ®Google Scholar
• Yu H, Shi L, Zhao S, et al. Triptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathway. Cardiovasc Toxicol. 2016 Oct;16(4):325–335. 10.1007/s12012-015-9342-y. PubMed PMID: 26391895; eng.
   PubMed Web of Science ®Google Scholar
• Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009 Feb 6;158(3):995–1006. PubMed PMID: 18675321; eng.
   PubMed Web of Science ®Google Scholar
• Joshi G, Sultana R, Tangpong J, et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res. 2005 Jan 01;39(11):1147–1154.
   PubMed Web of Science ®Google Scholar
• Meyers CA. How chemotherapy damages the central nervous system. J Biol. 2008;7(4):11. PubMed PMID: 18439322; PubMed Central PMCID: PMCPMC2397491. eng.
   PubMedGoogle Scholar
• Cummings J, Anderson L, Willmott N, et al. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer (Oxford, England: 1990). 1991;27(5):532–535. PubMed PMID: 1647181; eng.
   PubMed Web of Science ®Google Scholar
• Singal PK, Li T, Kumar D, et al. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000 Apr;207(1–2):77–86. PubMed PMID: 10888230; eng.
   PubMed Web of Science ®Google Scholar
• De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol. 2001 Mar 9;415(1):1–11. PubMed PMID: 11245845; eng.
   PubMed Web of Science ®Google Scholar
• Aluise CD, Sultana R, Tangpong J, et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol. 2010;678:147–156. PubMed PMID: 20738017; eng.
   PubMed Web of Science ®Google Scholar
• Trask PC, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000 Jun;18(11):2316–2326. PubMed PMID: 10829053; eng.
   PubMed Web of Science ®Google Scholar
• Macleod JE, DeLeo JA, Hickey WF, et al. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res. 2007 Jul 19;181(1):168–172. PubMed PMID: 17509697; PubMed Central PMCID: PMCPMC4012416. eng.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Tallarida RJ. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’. J Clin Pharm Ther. 2010 Jun;35(3):249–255. PubMed PMID: 20831527; PubMed Central PMCID: PMCPMC3249620. eng.
   PubMed Web of Science ®Google Scholar
• Joshi G, Aluise CD, Cole MP, et al. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience. 2010 Mar 31;166(3):796–807. PubMed PMID: 20096337; PubMed Central PMCID: PMCPMC2852883. eng.
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: from basic research to clinical application. Am J Med. 1991 Sep 30;91(3c):31s–38s. PubMed PMID: 1928209; eng.
   PubMed Web of Science ®Google Scholar
• Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008 Nov;13(11):1159–1170. PubMed PMID: 19090810; eng.
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Bailey-Downs L, Sosnowska D, et al. Vascular oxidative stress in aging: a homeostatic failure due to dysregulation of NRF2-mediated antioxidant response. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H363–72. PubMed PMID: 21602469; PubMed Central PMCID: PMCPMC3154665. eng.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Lu W, Ogasawara MA, et al. Redox regulation of cell survival. Antioxid Redox Signal. 2008 Aug;10(8):1343–1374. PubMed PMID: 18522489; PubMed Central PMCID: PMCPMC2932530. eng.
   PubMed Web of Science ®Google Scholar
• Aluise CD, Miriyala S, Noel T, et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med. 2011 Jun 1;50(11):1630–1638. PubMed PMID: 21421044; eng.
   PubMed Web of Science ®Google Scholar
• Tangpong J, Cole MP, Sultana R, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem. 2007 Jan;100(1):191–201. PubMed PMID: 17227439; eng.
   PubMed Web of Science ®Google Scholar
• Butterfield DA. The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med. 2014 Sep;74:157–174. PubMed PMID: 24996204; PubMed Central PMCID: PMCPMC4146642. eng.
   PubMed Web of Science ®Google Scholar
• Li R, Li J, Huang Y, et al. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice. Int J Biol Sci. 2018;14(11):1411–1425. PubMed PMID: 30262993; PubMed Central PMCID: PMCPMC6158724. eng.
   PubMed Web of Science ®Google Scholar
• Tangpong J, Miriyala S, Noel T, et al. Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia mangostana. Neuroscience. 2011 Feb;23(175):292–299. PubMed PMID: 21074598; PubMed Central PMCID: PMCPMC3136166. eng.
   PubMed Web of Science ®Google Scholar
• Shah FA, Kury LA, Li T, et al. Polydatin attenuates neuronal loss via reducing neuroinflammation and oxidative stress in rat MCAO models. Front Pharmacol. 2019;10:663. PubMed PMID: 31293416; PubMed Central PMCID: PMCPMC6606791. eng.
   PubMed Web of Science ®Google Scholar
• Corpas R, Grinan-Ferre C, Rodriguez-Farre E, et al. Resveratrol induces brain resilience against Alzheimer neurodegeneration through proteostasis enhancement. Mol Neurobiol. 2019 Feb;56(2):1502–1516. 10.1007/s12035-018-1157-y. PubMed PMID: 29948950; eng.
   PubMed Web of Science ®Google Scholar
• Dou Z, Rong X, Zhao E, et al. Neuroprotection of resveratrol against focal cerebral ischemia/reperfusion injury in mice through a mechanism targeting gut-brain axis. Cell Mol Neurobiol. 2019 Aug;39(6):883–898. 10.1007/s10571-019-00687-3. PubMed PMID: 31140018; eng.
   PubMed Web of Science ®Google Scholar
• Li L, Tan HP, Liu CY, et al. Polydatin prevents the induction of secondary brain injury after traumatic brain injury by protecting neuronal mitochondria. Neural Regen Res. 2019 Sep;14(9):1573–1582. PubMed PMID: 31089056; PubMed Central PMCID: PMCPMC6557083. eng.
   PubMed Web of Science ®Google Scholar
• Huang K, Chen C, Hao J, et al. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells. Mol Cell Endocrinol. 2015;399:178–189.
   PubMed Web of Science ®Google Scholar
• Amri A, Chaumeil JC, Sfar S, et al. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release. 2012 Mar 10;158(2):182–193. PubMed PMID: 21978644; eng.
   PubMed Web of Science ®Google Scholar
• Liu LT, Guo G, Wu M, et al. The progress of the research on cardio-vascular effects and acting mechanism of polydatin. Chin J Integr Med. 2012 Sep;18(9):714–719. PubMed PMID: 22936326; eng.
   PubMed Web of Science ®Google Scholar